In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes. A recent French study reported that aromatic amines in hair dye ...

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations. The results of a new study 1 suggested that the ...

The conference will be held January 13-16, 2025 in San Francisco, CA. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development ...

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a ...

Did you miss any of our print issues this year? Don’t worry, they are still available online. In an increasingly digital world, where news moves swiftly and time is crunched, digital reading has ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.